{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "15335301",
  "DateCompleted": {
    "Year": "2005",
    "Month": "06",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "11",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1744-764X",
      "JournalIssue": {
        "Volume": "3",
        "Issue": "5",
        "PubDate": {
          "Year": "2004",
          "Month": "Sep"
        }
      },
      "Title": "Expert opinion on drug safety",
      "ISOAbbreviation": "Expert Opin Drug Saf"
    },
    "ArticleTitle": "Sexual dysfunction associated with antidepressant drugs.",
    "Pagination": {
      "StartPage": "457",
      "EndPage": "470",
      "MedlinePgn": "457-70"
    },
    "Abstract": {
      "AbstractText": [
        "The term 'sexual dysfunction' describes a disturbance in sexual desire and the psychophysiological changes that characterise the normal sexual response cycle, and cause marked personal distress and interpersonal difficulty. Epidemiological studies indicate that sexual dysfunction is common in the general population, but more common in depressed individuals in community settings and clinical samples. Most antidepressant drugs have adverse effects on sexual function, but accurate identification of the incidence of treatment-emergent dysfunction has proved troublesome. Futhermore, investigations of sexual dysfunction associated with antidepressants have one or more methodological flaws. There may be some advantages for bupropion, moclobemide, nefazodone and reboxetine over other antidepressants. Many approaches have been adopted for management of patients with sexual dysfunction associated with antidepressant treatment, including waiting for the problem to resolve, behavioural strategies to modify sexual technique, individual and couple psychotherapy, delaying the intake of antidepressants until after sexual activity, reduction in daily dosage, 'drug holidays', use of adjuvant treatments, and switching to a different antidepressant."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University Department of Mental Health, RSH Hospital, RSH Hospital, Graham Road, Southampton, SO14 0YG, UK. dsb1@soton.ac.uk"
          }
        ],
        "LastName": "Baldwin",
        "ForeName": "David S",
        "Initials": "DS"
      }
    ],
    "PublicationTypeList": [
      "Comparative Study",
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Opin Drug Saf",
    "NlmUniqueID": "101163027",
    "ISSNLinking": "1474-0338"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "pharmacology"
      ],
      "DescriptorName": "Antidepressive Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Case-Control Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cross-Over Studies"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Administration Schedule"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Ejaculation"
    },
    {
      "QualifierName": [
        "chemically induced",
        "drug therapy"
      ],
      "DescriptorName": "Erectile Dysfunction"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Libido"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Orgasm"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Phytotherapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prevalence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Randomized Controlled Trials as Topic"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Sexual Behavior"
    },
    {
      "QualifierName": [
        "chemically induced",
        "drug therapy",
        "etiology",
        "therapy"
      ],
      "DescriptorName": "Sexual Dysfunction, Physiological"
    }
  ],
  "NumberOfReferences": "96"
}